Abstract:Background: Carriers of the E40K loss-of-function variant in Angiopoietin-like 4 (ANGPTL4), have lower plasma triglyceride levels as well as lower rates of coronary artery disease (CAD) and type 2 diabetes (T2D). These genetic data suggest ANGPTL4 inhibition as a potential therapeutic target for cardiometabolic diseases. However, it is unknown whether the association between E40K and human diseases is due to linkage disequilibrium confounding. The broader impact of genetic ANGPTL4 inhibition is also unknown, raising uncertainties about the safety and validity of this target. Methods: To assess the impact of ANGPLT4 inhibition, we evaluated whether E40K and other loss-of-function variants in ANGPTL4 influenced a wide range of health markers and diseases using 29 publicly available genome-wide association meta-analyses of cardiometabolic traits and diseases, as well as 1589 diseases assessed in electronic health records within FinnGen (n = 309,154). To determine whether these relationships were likely causal, and not driven by other correlated variants, we used the Bayesian fine mapping algorithm CoPheScan. Results: The CoPheScan posterior probability of E40K being the causal variant for triglyceride levels was 99.99 %, validating the E40K to proxy lifelong lower activity of ANGPTL4. The E40K variant was associated with lower risk of CAD (odds ratio [OR] = 0.84, 95 % CI = 0.81 to 0.87, p=3.6e-21) and T2D (OR = 0.91, 95 % CI = 0.87 to 0.95, p=2.8e-05) in GWAS meta-analyses, with results replicated in FinnGen. These significant results were also replicated using other rare loss-of-function variants identified through whole exome sequencing in 488,278 participants of the UK Biobank. Using a Mendelian randomization study design, the E40K variant effect on cardiometabolic diseases was concordant with lipoprotein lipase enhancement (r = 0.82), but not hepatic lipase enhancement (r = -0.10), suggesting that ANGPTL4 effects on cardiometabolic diseases are potentially mainly mediated through lipoprotein lipase. After correction for multiple testing, the E40K variant did not significantly increase the risk of any of the 1589 diseases tested in FinnGen. Conclusions: ANGPTL4 inhibition may represent a potentially safe and effective target for cardiometabolic diseases prevention or treatment.

Trans -Ancestry Fine Mapping and Molecular Assays Identify Regulatory Variants at the ANGPTL8 HDL-C GWAS Locus

A novel variant associated with HDL-C levels by modifying DAGLB expression levels: An annotation-based genome-wide association study

Association Analyses of East Asian Individuals and Trans-Ancestry Analyses with European Individuals Reveal New Loci Associated with Cholesterol and Triglyceride Levels

Novel Common Variants Associated with Body Mass Index and Coronary Artery Disease Detected Using a Pleiotropic Cfdr Method.

Newly identified loci that influence lipid concentrations and risk of coronary artery disease

Identifying the Lipidomic Effects of a Rare Loss-of-Function Deletion in ANGPTL3

Common Variants at 30 Loci Contribute to Polygenic Dyslipidemia

The Cross-Sectional Study of Hepatic Lipase SNPs and Plasma Lipid Levels

Transferability and Fine Mapping of Genome-Wide Associated Loci for Lipids in African Americans

Association of Genetic Loci with Blood Lipids in the Chinese Population

Rare variants in long non-coding RNAs are associated with blood lipid levels in the TOPMed Whole Genome Sequencing Study

Impact of loss-of-function in angiopoietin-like 4 on the human phenome

Functional Variant in the SLC22A3-LPAL2-LPA Gene Cluster Contributes to the Severity of Coronary Artery Disease

Abstract 150: Decoding the Variant-to-function Relationship for LIPA , A Risk Locus for Cad

Genetic Variants at Newly Identified Lipid Loci Are Associated with Coronary Heart Disease in a Chinese Han Population.

Exome Chip Meta-Analysis Identifies Novel Loci and East Asian–specific Coding Variants That Contribute to Lipid Levels and Coronary Artery Disease

Erratum: A Rare Variant in APOC3 is Associated with Plasma Triglyceride and VLDL Levels in Europeans

ANGPTL8 in cardio-metabolic diseases.

Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease.

Genetic Variant R952q In Lrp8 Is Associated With Increased Plasma Triglyceride Levels In Patients With Early-Onset Cad And Mi

Effects of Genetic Variants on Lipid Parameters and Dyslipidemia in A Chinese Population